keyword
MENU ▼
Read by QxMD icon Read
search

Multiple sclerosis treatments

keyword
https://www.readbyqxmd.com/read/28108364/from-natalizumab-to-fingolimod-in-eight-weeks-immunological-clinical-and-radiological-data-in-quest-of-the-optimal-switch
#1
Andrea Harrer, Georg Pilz, Katrin Oppermann, Marlene Sageder, Shahrzad Afazel, Elisabeth Haschke-Becher, Theo Rispens, Annick de Vries, Mark McCoy, Vlado Stevanovic, Wolfgang Hitzl, Eugen Trinka, Jörg Kraus, Johann Sellner, Peter Wipfler
Natalizumab (NZB) discontinuation during a treatment change is associated with recurrence of disease activity in a significant proportion of multiple sclerosis (MS) patients. The immunological basis why disease reactivation occurs in selected patients is unresolved. In search of a prognostic biomarker for a safe and effective transition from NZB to fingolimod, we monitored five parameters related to pharmacokinetic and pharmacodynamic effects of the two drugs in 12 MS patients until six months on fingolimod...
January 17, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28108125/interventions-to-support-risk-and-benefit-understanding-of-disease-modifying-drugs-in-multiple-sclerosis-patients-a-systematic-review
#2
REVIEW
Gurpreet K Reen, Eli Silber, Dawn W Langdon
OBJECTIVE: The present review evaluates interventions that have been designed to improve understanding of the complex risk-benefit profiles of disease-modifying drugs (DMDs) in patients with Multiple Sclerosis (MS). METHODS: A systematic search conducted using PubMed, Embase, Google Scholar and PsycINFO identified 15 studies. Interventions which provided treatment information were present across a range of study designs. A narrative synthesis was conducted due to heterogeneity of research findings...
December 28, 2016: Patient Education and Counseling
https://www.readbyqxmd.com/read/28107165/interleukin-33-plasma-levels-in-patients-with-relapsing-remitting-multiple-sclerosis
#3
Fereshteh Alsahebfosoul, Ilnaz Rahimmanesh, Mansour Shajarian, Masoud Etemadifar, Nahid Sedaghat, Zahra Hejazi, Shamsi Naderi
Cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS). Interleukin (IL)-33, one of the recently discovered members of the IL-1 superfamily, is a dual functional cytokine involved in various autoimmune disorders. In a case-control study, venous blood was collected from healthy subjects categorized as control group (n=44) and MS patients (n=44). All recruited patients were clinically diagnosed with relapsing-remitting MS (RRMS), including patients without treatment (new identified cases, n=16) and those treated with interferon beta (IFN-β) (n=28)...
January 20, 2017: Biomolecular Concepts
https://www.readbyqxmd.com/read/28104260/robot-guided-ankle-sensorimotor-rehabilitation-of-patients-with-multiple-sclerosis
#4
Yunju Lee, Kai Chen, Yupeng Ren, Jongsang Son, Bruce A Cohen, James A Sliwa, Li-Qun Zhang
BACKGROUND: People with multiple sclerosis (MS) often develop symptoms including muscle weakness, spasticity, imbalance, and sensory loss in the lower limbs, especially at the ankle, which result in impaired balance and locomotion and increased risk of falls. Rehabilitation strategies that improve ankle function may improve mobility and safety of ambulation in patients with MS. This pilot study investigated effectiveness of a robot-guided ankle passive-active movement training in reducing motor and sensory impairments and improving balance and gait functions...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104258/the-impact-of-betaplus-program-on-patient-treatment-satisfaction-with-interferon-beta-1b-in-multiple-sclerosis-multicentric-cross-sectional-survey-in-the-western-balkan-countries
#5
Jelena Drulovic, Mirjana Cukic, Sanja Grgic, Evica Dincic, Ranko Raicevic, Congor Nadj, Gordana Toncev, Slobodan Vojinovic, Sarlota Mesaros, Darija Kisic Tepavcevic, Irena Dujmovic, Daliborka Tadic, Svetlana Miletic-Drakulic, Jelena Dackovic, Smiljana Kostic, Jevto Erakovic, Lorand Sakalas, Dejan Savic, Vesna Suknjaja, Vanja Martinovic, Gorica Maric, Tatjana Pekmezovic
BACKGROUND: Long-term treatment adherence to disease-modifying drugs (DMDs) may have significant impact on clinical outcomes in multiple sclerosis (MS). It has been recently emphasized that low treatment satisfaction (TS) may be an important factor for achieving high rates of treatment adherence. Interferon (IFN) beta-1b was the first DMD approved for the treatment of MS. The aims of our study were to assess TS in subjects with relapsing-remitting (RR) MS treated with IFN beta-1b in Serbia, Montenegro and the Republika Srpska, Bosnia and Herzegovina (B&H), and additionally, to evaluate the impact of patient support program on TS and adherence...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104252/novel-zebrafish-eae-model-a-quick-in-vivo-screen-for-multiple-sclerosis
#6
Pushkar Kulkarni, Swapna Yellanki, Raghavender Medishetti, Dharmarajan Sriram, Uday Saxena, Perumal Yogeeswari
INTRODUCTION: Pre-clinical drug discovery for multiple sclerosis (MS) is a labor intensive activity to perform in rodent models. This is owing to the long duration of disease induction and observation of treatment effects in an experimental autoimmune encephalomyelitis (EAE) model. We propose a novel adult zebrafish based model which offers a quick and simple protocol that can used to screen candidates as a step between in vitro experiments and rodent studies. The experiments conducted for this manuscript were to standardize a suitable model of EAE in adult zebrafish and validate it using known modulators...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104251/efficacy-safety-and-pharmacokinetics-of-natalizumab-in-japanese-multiple-sclerosis-patients-a-double-blind-randomized-controlled-trial-and-open-label-pharmacokinetic-study
#7
Takahiko Saida, Jun-Ichi Kira, Shuji Kishida, Takashi Yamamura, Yukiko Sudo, Kazutaka Ogiwara, J T Tibung, Nisha Lucas, Meena Subramanyam
BACKGROUND: Natalizumab, an anti-α4 integrin monoclonal antibody, has demonstrated efficacy in phase 2 and 3 studies of predominantly Caucasian patients with relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: To evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of natalizumab in Japanese RRMS patients. METHODS: This multicenter, phase 2 study included an open-label PK/PD study in 12 patients (part A) and a double-blind, placebo-controlled, randomized (computer-generated sequence) study in 94 patients (part B)...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104250/impact-of-daclizumab-versus-interferon-beta-1a-on-patient-reported-outcomes-in-relapsing-remitting-multiple-sclerosis
#8
Ying Liu, Timothy Vollmer, Eva Havrdova, Katherine Riester, Andrew Lee, Glenn Phillips, Ping Wang, Guido Sabatella
BACKGROUND: Patient-reported outcomes (PROs) provide information on treatment effects from the patient's perspective that complement outcomes on clinical measures. In DECIDE, daclizumab demonstrated superior efficacy in reducing relapses, 24-week confirmed disability progression, and brain lesions (assessed by magnetic resonance imaging [MRI]) versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. OBJECTIVE: To examine the impact of daclizumab versus interferon beta-1a on PROs in DECIDE...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104247/severe-rebound-after-withdrawal-of-fingolimod-treatment-in-patients-with-multiple-sclerosis
#9
Tuncay Gündüz, Murat Kürtüncü, Mefkure Eraksoy
No abstract text is available yet for this article.
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28103257/activation-of-the-jak-stat-signaling-pathway-after-in-vitro-stimulation-with-ifn%C3%A3-in-multiple-sclerosis-patients-according-to-the-therapeutic-response-to-ifn%C3%A3
#10
Isaac Hurtado-Guerrero, Maria Jesús Pinto-Medel, Patricia Urbaneja, Jose Luis Rodriguez-Bada, Antonio León, Miguel Guerrero, Óscar Fernández, Laura Leyva, Begoña Oliver-Martos
Interferon beta (IFNß) is a common treatment used for multiple sclerosis (MS) which acts through the activation of the JAK-STAT pathway. However, this therapy is not always effective and currently there are no reliable biomarkers to predict therapeutic response. We postulate that the heterogeneity in the response to IFNß therapy could be related to differential activation patterns of the JAK-STAT signaling pathway. Our aim was to evaluate the basal levels and the short term activation of this pathway after IFNß stimulation in untreated and IFNß treated patients, as well as according to therapeutic response...
2017: PloS One
https://www.readbyqxmd.com/read/28101629/treatment-of-ribbing-disease-with-5-year-follow-up-and-literature-review
#11
L L Zhang, W M Jiang, H L Yang, Z-P Luo
Ribbing disease, or multiple diaphyseal sclerosis, is a rare diaphyseal sclerosis of unknown etiology. Patients with this pathology usually present with asymmetric pain limited to the lower extremities. Though all efforts are made to relieve the progressive pain associated with Ribbing disease, no medical or surgical treatments have been established yet. In this case report, we followed up a Ribbing case with sclerotic bone fenestration for 5 years. The radiological changes and the clinical effects are described, and the different Ribbing treatments are then briefly reviewed...
January 18, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28101520/an-observational-study-of-alemtuzumab-following-fingolimod-for-multiple-sclerosis
#12
Mark Willis, Owen Pearson, Zsolt Illes, Tobias Sejbaek, Christian Nielsen, Martin Duddy, Kate Petheram, Caspar van Munster, Joep Killestein, Clas Malmeström, Emma Tallantyre, Neil Robertson
OBJECTIVE: To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab. METHODS: Patients with relapsing MS treated sequentially with fingolimod then alemtuzumab who experienced significant subsequent disease activity were identified by personal communication with 6 different European neuroscience centers. RESULTS: Nine patients were identified...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28101047/acute-anterior-uveitis-in-a-patient-taking-fingolimod-fty720-for-multiple-sclerosis
#13
Heather Gwen Mack, Melissa Chih-Hui Tien, Owen Bruce White
Fingolimod is an oral sphingosine-1-phosphate (S1P) receptor modulator and the first oral therapy for relapsing-remitting multiple sclerosis. Its use has been complicated by a low rate of cystoid macular edema usually in the first 3 months after commencement of the medication. We report the case of a 34-year-old male with relapsing-remitting multiple sclerosis, who developed acute anterior uveitis on day 5 of fingolimod treatment. He responded to appropriate treatment and cessation of drug, but developed low-grade chronic anterior uveitis without cystoid macular edema...
September 2016: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28100738/mir-142-3p-is-a-key-regulator-of-il-1%C3%AE-dependent-synaptopathy-in-neuroinflammation
#14
Georgia Mandolesi, Francesca De Vito, Alessandra Musella, Antonietta Gentile, Silvia Bullitta, Diego Fresegna, Helena Sepman, Claudio Di Sanza, Nabila Haji, Francesco Mori, Fabio Buttari, Emerald Perlas, Maria Teresa Ciotti, Eran Hornstein, Irene Bozzoni, Carlo Presutti, Diego Centonze
: MicroRNAs (miRNA) play an important role in post-transcriptional gene regulation of several physiological and pathological processes. In multiple sclerosis (MS), a chronic inflammatory and degenerative disease of the CNS, and in its mouse model, the experimental autoimmune encephalomyelitis (EAE), miRNA dysregulation has been mainly related to immune system dysfunction and white matter (WM) pathology. However, little is known about their role in gray matter pathology. Here, we explored miRNA involvement in the inflammation-driven alterations of synaptic structure and function, collectively known as synaptopathy, a neuropathological process contributing to excitotoxic neurodegeneration in MS/EAE...
January 18, 2017: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/28100092/sample-size-requirements-for-one-year-treatment-effects-using-deep-gray-matter-volume-from-3t-mri-in-progressive-forms-of-multiple-sclerosis
#15
Gloria Kim, Renxin Chu, Fawad Yousuf, Shahamat Tauhid, Lynn Stazzone, Maria K Houtchens, James M Stankiewicz, Christopher Severson, Dorlan Kimbrough, Francisco Quintana, Tanuja Chitnis, Howard L Weiner, Brian C Healy, Rohit Bakshi
OBJECTIVE: The subcortical deep gray matter (DGM) develops selective, progressive, and clinically-relevant atrophy in progressive forms of multiple sclerosis (PMS). This patient population is the target of active neurotherapeutic development, requiring the availability of outcome measures. We tested a fully automated MRI analysis pipeline to assess DGM atrophy in PMS. DESIGN/METHODS: Consistent 3D T1-weighted high-resolution 3T brain MRI was obtained over one year in 19 consecutive patients with PMS [15 secondary progressive, 4 primary progressive, 53% women, age (mean±SD) 50...
January 19, 2017: International Journal of Neuroscience
https://www.readbyqxmd.com/read/28100077/effects-of-m2000-d-mannuronic-acid-on-learning-memory-retrieval-and-associated-determinants-in-a-rat-model-of-alzheimer-s-disease
#16
Somayeh Athari Nik Azm, Mohammadreza Vafa, Mohammad Sharifzadeh, Majid Safa, Anis Barati, Abbas Mirshafiey
The d-mannuronic acid (M2000) is a novel nonsteroidal anti-inflammatory drug that has immunosuppressive effects together with antioxidant property. M2000 has shown a notable efficacy in experimental models of multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome. In this work, the effect of M2000 on the treatment of Alzheimer's disease (AD) was performed by Morris water maze experiment, and the immunological assessments were carried out by Western blot, apoptosis (procaspase-3, Bax/Bcl2, P53), enzymatic (superoxide dismutase [SOD]), and nonenzymatic oxidative stress (malondialdehyde [MDA]) tests...
February 2017: American Journal of Alzheimer's Disease and Other Dementias
https://www.readbyqxmd.com/read/28099564/guideline-for-multiple-sclerosis-treatment-in-brazil-consensus-from-the-neuroimmunology-scientific-department-of-the-brazilian-academy-of-neurology
#17
Elizabeth Regina Comini-Frota, Cláudia C F Vasconcelos, Maria Fernanda Mendes
Multiple sclerosis has become an ever-increasing challenge to neurologists. With the release of the latest medications on the market, Brazilian neurologists feel divided between following their patients' evolution in accordance with the strict rules established by the Brazilian Ministry of Health regarding drug distribution, or following disease progression and worsening in accordance with the evidence in the literature. Therefore, a systematic review of the main published treatment guidelines was conducted and an escalating therapy proposed for guiding multiple sclerosis patient treatment in Brazil...
January 2017: Arquivos de Neuro-psiquiatria
https://www.readbyqxmd.com/read/28099554/no-correlation-was-observed-between-vitamin-d-levels-and-disability-of-patients-with-multiple-sclerosis-between-latitudes-18%C3%A2-and-30%C3%A2-south
#18
Yara Dadalti Fragoso, Tarso Adoni, Soniza Vieira Alves-Leon, Samira L Apostolos-Pereira, Walter Oleschko Arruda, Joseph B Bidin Brooks, Henrique S Rodrigues Cal, Carlos A Albuquerque Damasceno, Paulo Diniz Gama, Marcus V Magno Goncalves, Carlos A da Silva de Jesus, Suzana C Nunes Machado, Letícia Fezer Mansur, Andre P da Cunha Matta, Maria Fernanda Mendes, Rogerio Rizo Morales, Adaucto Wanderley da Nobrega-Jr, Monica K Fiuza Parolin, Mario Pietro Peres, Marlise de Castro Ribeiro, Heloisa Helena Ruocco, Simone Scherpenhuijzen, Fabio Siquinelli, Patrick N Stoney, Daniel Lima Varela, Audred Cristina Biondo Eboni, Caroline Vieira Spessotto, Elisa Teixeira da Rocha, Pamela Emanuele Lacerda
Objective: Vitamin D has taken center stage in research and treatment of multiple sclerosis (MS). The objective of the present study was to assess the serum vitamin D levels of a large population of patients with MS and controls living in a restricted tropical area. Methods: Data from 535 patients with MS and 350 control subjects were obtained from 14 cities around the Tropic of Capricorn. Results: The mean serum 25-OH vitamin D level was 26...
January 2017: Arquivos de Neuro-psiquiatria
https://www.readbyqxmd.com/read/28099414/neurotoxic-reactive-astrocytes-are-induced-by-activated-microglia
#19
Shane A Liddelow, Kevin A Guttenplan, Laura E Clarke, Frederick C Bennett, Christopher J Bohlen, Lucas Schirmer, Mariko L Bennett, Alexandra E Münch, Won-Suk Chung, Todd C Peterson, Daniel K Wilton, Arnaud Frouin, Brooke A Napier, Nikhil Panicker, Manoj Kumar, Marion S Buckwalter, David H Rowitch, Valina L Dawson, Ted M Dawson, Beth Stevens, Ben A Barres
Reactive astrocytes are strongly induced by central nervous system (CNS) injury and disease, but their role is poorly understood. Here we show that a subtype of reactive astrocytes, which we termed A1, is induced by classically activated neuroinflammatory microglia. We show that activated microglia induce A1 astrocytes by secreting Il-1α, TNF and C1q, and that these cytokines together are necessary and sufficient to induce A1 astrocytes. A1 astrocytes lose the ability to promote neuronal survival, outgrowth, synaptogenesis and phagocytosis, and induce the death of neurons and oligodendrocytes...
January 18, 2017: Nature
https://www.readbyqxmd.com/read/28094009/q-space-myelin-map-imaging-a-new-imaging-technique-for-treatment-evaluation-in-multiple-sclerosis
#20
Jun-Ichi Kira
No abstract text is available yet for this article.
January 4, 2017: Journal of the Neurological Sciences
keyword
keyword
114918
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"